Skip to main content
Fig. 4 | Clinical Hypertension

Fig. 4

From: A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy

Fig. 4

Response rate of low-density lipoprotein cholesterol (LDL-C) and control rate of sitting systolic blood pressure (SiSBP) from baseline at week 8. A Response rate of LDL-C. B Control rate of SiSBP

Back to article page

Clinical Hypertension

ISSN: 2056-5909

Contact us